Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Uterine Cervical Neoplasms 1Endometrial Adenocarcinoma 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Advanced Hepatocellular Carcinoma (HCC) 1Acrocephalosyndactylia 1

Interventions

Taxes 5Paclitaxel 5Carboplatin 4Immunoglobulin G 2Disulfides 2Cisplatin 2Bevacizumab 2temsirolimus 1pegfilgrastim 1nintedanib 1ixabepilone 1cediranib 1brivanib 1Sunitinib 1Sirolimus 1Radiotherapy, Intensity-Modulated 1Platinum 1Metformin 1Medroxyprogesterone Acetate 1Medroxyprogesterone 1MK 2206 1Granulocyte Colony-Stimulating Factor 1Gemcitabine 1Filgrastim 1Epothilones 1Doxorubicin 1Brachytherapy 1AZD 6244 1ALK1-Fc fusion protein, human 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Endometrial Adenocarcinoma × brivanib × Clear all
NCT00888173 2017-12-06

Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer

GOG Foundation

Phase 2 Completed
45 enrolled 10 charts
GenitourinaryGynecologic

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡